This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating
alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of
their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge,
individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or
a placebo. This part of the study will last 12 weeks, with regular measurements of drinking
level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of
the study.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)